share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Kewalramani Reshma

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Kewalramani Reshma

福泰制药 | 4:持股变动声明-高管 Kewalramani Reshma
美股SEC公告 ·  07/24 16:12
Moomoo AI 已提取核心信息
Vertex Pharmaceuticals CEO & President, Kewalramani Reshma, completed a sale of 15,202 shares of the company's common stock on July 22, 2024. The transaction was executed at a price of $497.00 per share, resulting in a total sale value of $7,555,394. Following the sale, Reshma's direct holdings in Vertex Pharmaceuticals amount to 106,172 shares. The sale took place in an open market transaction, as reported in the company's filing.
Vertex Pharmaceuticals CEO & President, Kewalramani Reshma, completed a sale of 15,202 shares of the company's common stock on July 22, 2024. The transaction was executed at a price of $497.00 per share, resulting in a total sale value of $7,555,394. Following the sale, Reshma's direct holdings in Vertex Pharmaceuticals amount to 106,172 shares. The sale took place in an open market transaction, as reported in the company's filing.
福泰制药的首席执行官和总裁Kewalramani Reshma于2024年7月22日出售了15,202股公司普通股。交易价格为每股497.00美元,总销售价值为7,555,394美元。出售后,Reshma在福泰制药的直接持股总量为106,172股。此次销售是在公开市场交易中进行的,如公司所述。
福泰制药的首席执行官和总裁Kewalramani Reshma于2024年7月22日出售了15,202股公司普通股。交易价格为每股497.00美元,总销售价值为7,555,394美元。出售后,Reshma在福泰制药的直接持股总量为106,172股。此次销售是在公开市场交易中进行的,如公司所述。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息